Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors
Charles M Rudin, Hardev S Pandha, Matthew Zibelman, Wallace L Akerley, Kevin J Harrington, Daphne Day, Andrew G Hill, Steven J O'Day, Timothy D Clay, Gavin M Wright, Ross R Jennens, David E Gerber, Jonathan E Rosenberg, Christy Ralph, David C Campbell, Brendan D Curti, Jaime R Merchan, Yixin Ren, Emmett V Schmidt, Lisa Guttman, Sumati Gupta
Journal for ImmunoTherapy of Cancer Jan 2023, 11 (1) e005007; DOI: 10.1136/jitc-2022-005007